Arikayce Kit — Competitive Intelligence Brief

Arikayce Kit (AMIKACIN) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aminoglycoside Antibacterial. Area: Immunology.

marketed Aminoglycoside Antibacterial Immunology Small molecule

Target snapshot

Arikayce Kit (AMIKACIN) — Bristol-Myers Squibb. Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Arikayce Kit TARGET	AMIKACIN	Bristol-Myers Squibb	marketed	Aminoglycoside Antibacterial		1981-01-01
Netromycin	NETILMICIN		marketed	Aminoglycoside Antibacterial		1983-01-01
Kanacin	KANAMYCIN	Bristol-Myers Squibb	marketed	Aminoglycoside Antibacterial	Gap junction beta-2 protein	1973-01-01
Garamycin	GENTAMICIN	Merck & Co.	marketed	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Cortisporin	NEOMYCIN	Pfizer	marketed	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 1	1957-01-01
loteprednol etabonate and tobramycin	loteprednol etabonate and tobramycin	Bausch & Lomb Incorporated	marketed	Aminoglycoside Antibacterial [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aminoglycoside Antibacterial class)

1. Bristol-Myers Squibb · 2 drugs in this class
2. · 1 drug in this class
3. Merck & Co. · 1 drug in this class
4. Pfizer · 1 drug in this class